Protective effect of rectal ozone therapy against oxidative stress in immunoglobulin A deficiency

The excess in the production of free radicals produces an imbalance between the prooxidants and antioxidants in favor of the former; which causes loss of redox control signaling and damage to biomolecules such as proteins, lipids and deoxyribonucleic acid. When homeostasis is altered in the redox metabolism of cells that participate in the immune response, they usually evolve into a situation of oxidative stress that facilitates cell dysfunction and death. The objective of our work was to study the effect of ozone on the regulation of redox status, necessary to maintain normal immune function in patients with immunoglobulin A deficiency. Patients and methods: The Research Ethics Committee conducted and approved a clinical trial and whose patients gave informed consent for inclusion. Sixty patients were randomly assigned to two groups: one receiving ozone rectal insufflation (study group-SG) and the second using Hebertrans® (control-GC group), subcutaneously. Pro-oxidant parameters (malondialdehyde-MDA and advanced oxidation protein products-AOPP) and antioxidant parameters (superoxide dismutase1-SOD1, catalase-CAT, glutathione peroxidase-GPx and total antioxidant capacity of serum) were measured. They were measured at the beginning and one month after treatment. Results: In the SG the MDA and the APOP of patients ?15 years, decreased significantly (p = 0.000) with respect to the control group. SOD1 in the SG increased in patients ?15 years (p = 0.006) and from 16 to 30 years of age (p = 0.040) with respect to GC. CAT in patients ?15 years of the SG increased significantly (p=0.001) with respect to initial values. The final result of the total antioxidant capacity in the SG was significantly (p=0.000) higher in patients ? 15 years, similar results were obtained in GPx (p=0.013). Conclusions: With ozone therapy, beneficial effects on the oxidation reduction balance were achieved. Medical ozone therapy may be an additional treatment option, for immunoglobulin A deficient patients with oxidative stress.